Sophia J Fanelli1, Mohammed Elzeneini2, Lauren E Meece2, Ahmad Mahmoud2, Eric I Jeng3, Neil Harris4, Mustafa M Ahmed2. 1. College of Medicine, University of Florida, Gainesville, Florida, USA. 2. Division of Cardiovascular Medicine, University of Florida, Gainesville, Florida, USA. 3. Division of Thoracic and Cardiovascular Surgery, University of Florida, Gainesville, Florida, USA. 4. Department of Pathology, Immunology & Laboratory Medicine, University of Florida, Gainesville, Florida, USA.
Abstract
BACKGROUND AND AIM: The role of thromboelastography (TEG) in managing antiplatelet therapy (APT) in left ventricular assist devices (LVADs) is controversial. Our aim was to determine whether removal of TEG from an LVAD-specific APT protocol reduced late-onset bleeding without increasing thromboembolic complications. METHODS: We performed a single-center, retrospective cohort study including all recipients of a continuous-flow LVAD between April 2005 and November 2019 (n = 293). LVAD recipients before June 1, 2017 (n = 221) whose APT was monitored and adjusted using TEG were compared with LVAD recipients after June 1, 2017 (n = 72) where TEG was not utilized. Occurrence of late-onset bleeding events after postoperative Day 7 and thromboembolic events were collected. APT doses, warfarin use and International normalized ratio (INR) values were collected at discharge and at 1, 3, 6, and 12-months postimplantation. RESULTS: Over a median 12-month follow-up, INTERMACS major bleeding events occurred in 35% of patients where TEG was utilized compared with 29% where TEG was not utilized (p = 0.375), and procedural intervention was required in 29% compared with 18%, respectively (p = 0.058). Use of TEG was associated with higher doses of aspirin (>325 mg) (41% compared with none) and use of a second antiplatelet (dipyridamole) (43% compared to 1%). Despite this, there was no significant difference in thromboembolic events (15% in each). CONCLUSIONS: Our study suggests the use of TEG led to increased doses of aspirin as well as adding a second antiplatelet agent, without improving outcomes in LVAD recipients. Furthermore, the removal of TEG from an LVAD-specific APT protocol did not worsen thromboembolic outcomes.
BACKGROUND AND AIM: The role of thromboelastography (TEG) in managing antiplatelet therapy (APT) in left ventricular assist devices (LVADs) is controversial. Our aim was to determine whether removal of TEG from an LVAD-specific APT protocol reduced late-onset bleeding without increasing thromboembolic complications. METHODS: We performed a single-center, retrospective cohort study including all recipients of a continuous-flow LVAD between April 2005 and November 2019 (n = 293). LVAD recipients before June 1, 2017 (n = 221) whose APT was monitored and adjusted using TEG were compared with LVAD recipients after June 1, 2017 (n = 72) where TEG was not utilized. Occurrence of late-onset bleeding events after postoperative Day 7 and thromboembolic events were collected. APT doses, warfarin use and International normalized ratio (INR) values were collected at discharge and at 1, 3, 6, and 12-months postimplantation. RESULTS: Over a median 12-month follow-up, INTERMACS major bleeding events occurred in 35% of patients where TEG was utilized compared with 29% where TEG was not utilized (p = 0.375), and procedural intervention was required in 29% compared with 18%, respectively (p = 0.058). Use of TEG was associated with higher doses of aspirin (>325 mg) (41% compared with none) and use of a second antiplatelet (dipyridamole) (43% compared to 1%). Despite this, there was no significant difference in thromboembolic events (15% in each). CONCLUSIONS: Our study suggests the use of TEG led to increased doses of aspirin as well as adding a second antiplatelet agent, without improving outcomes in LVAD recipients. Furthermore, the removal of TEG from an LVAD-specific APT protocol did not worsen thromboembolic outcomes.
Authors: Joseph G Rogers; Francis D Pagani; Antone J Tatooles; Geetha Bhat; Mark S Slaughter; Emma J Birks; Steven W Boyce; Samer S Najjar; Valluvan Jeevanandam; Allen S Anderson; Igor D Gregoric; Hari Mallidi; Katrin Leadley; Keith D Aaronson; O H Frazier; Carmelo A Milano Journal: N Engl J Med Date: 2017-02-02 Impact factor: 91.245
Authors: Mandeep R Mehra; Daniel J Goldstein; Nir Uriel; Joseph C Cleveland; Melana Yuzefpolskaya; Christopher Salerno; Mary N Walsh; Carmelo A Milano; Chetan B Patel; Gregory A Ewald; Akinobu Itoh; David Dean; Arun Krishnamoorthy; William G Cotts; Antone J Tatooles; Ulrich P Jorde; Brian A Bruckner; Jerry D Estep; Valluvan Jeevanandam; Gabriel Sayer; Douglas Horstmanshof; James W Long; Sanjeev Gulati; Eric R Skipper; John B O'Connell; Gerald Heatley; Poornima Sood; Yoshifumi Naka Journal: N Engl J Med Date: 2018-03-11 Impact factor: 91.245
Authors: Alejandro Lemor; Alexander Michaels; Waleed Al-Darzi; Gabriel A Hernandez; Youssef Nasr; Pedro Villablanca; Vanessa Blumer; Cristina Tita; Celeste T Williams; Yelena Selektor; David E Lanfear; JoAnn Lindenfeld; Jennifer Cowger Journal: ASAIO J Date: 2020 Nov/Dec Impact factor: 2.872
Authors: Paul A Harris; Robert Taylor; Brenda L Minor; Veida Elliott; Michelle Fernandez; Lindsay O'Neal; Laura McLeod; Giovanni Delacqua; Francesco Delacqua; Jacqueline Kirby; Stephany N Duda Journal: J Biomed Inform Date: 2019-05-09 Impact factor: 6.317
Authors: Daniel J Goldstein; Keith D Aaronson; Antone J Tatooles; Scott C Silvestry; Valluvan Jeevanandam; Robert Gordon; David R Hathaway; Kevin B Najarian; Mark S Slaughter Journal: JACC Heart Fail Date: 2015-03-11 Impact factor: 12.035
Authors: Andrew J Boyle; Stuart D Russell; Jeffrey J Teuteberg; Mark S Slaughter; Nader Moazami; Francis D Pagani; O Howard Frazier; Gerald Heatley; David J Farrar; Ranjit John Journal: J Heart Lung Transplant Date: 2009-09 Impact factor: 10.247
Authors: Douglas L Jennings; Edward T Horn; Haifa Lyster; Anthony L Panos; Jeffrey J Teuteberg; Hans B Lehmkuhl; Alexandra Perez; Michael A Shullo Journal: ASAIO J Date: 2016 Jan-Feb Impact factor: 2.872